The STRIDE trial semaglutide results showed better walking capacity in people with leg artery disease and type 2 diabetes. After 52 weeks, maximum treadmill walking distance improved by 21% with semaglutide versus 8% with placebo, a look-alike treatment without the medicine. The paper estimated a 13% walking advantage versus placebo. That finding does not tell us what happens in people without diabetes or with a compounded formulation.
What question did STRIDE ask?
Could semaglutide help people walk farther when narrowed leg arteries make walking painful?
Peripheral artery disease, or PAD, means narrowed arteries reduce blood flow to the limbs, usually the legs. Intermittent claudication means leg pain that appears with walking and eases with rest. Even relatively early PAD can make ordinary outings harder.
Semaglutide is a GLP-1 medicine, meaning it copies a gut-hormone signal involved in appetite and blood sugar. STRIDE asked about walking function, rather than making weight loss its main measure. The trial appeared in The Lancet in 2025.
Who joined, and for how long?
Researchers assigned 792 adults by chance to weekly semaglutide or placebo, 396 in each group. Everyone had type 2 diabetes and stable walking pain from PAD. The minimum age was 18, and the median age was 68, meaning half were younger and half older. About one-quarter were women.
Participants had to walk at least 200 metres without pain on a flat treadmill. They also had to show limited walking capacity on a steeper test. Blood-pressure comparisons between the ankle or toe and the arm confirmed reduced circulation.
People whose walking was limited by another condition were excluded. So were people with recent artery-opening procedures or plans for one, recent major cardiovascular events, or severe heart failure. This was not a trial of every cause of painful walking.
Treatment lasted 52 weeks, followed by five weeks off treatment. The study target was semaglutide 1 mg weekly, reached gradually. That is a trial fact; an individual's prescriber sets the actual dose. The STRIDE registry record describes the screening rules and schedule.
STRIDE trial semaglutide results: the walking test
The primary endpoint—the main result chosen before the trial started—was maximum walking distance at week 52 divided by the starting distance.
The constant-load treadmill test kept speed and slope fixed: 2 miles per hour at a 12% incline. Participants continued after pain began until pain prevented further walking. This is different from measuring the distance before pain first appears.
| Main walking result at 52 weeks | Semaglutide | Placebo |
|---|---|---|
| Median ratio to starting maximum distance | 1.21 | 1.08 |
| Equivalent improvement from starting distance | 21% | 8% |
The estimated treatment ratio was 1.13, with a 95% confidence interval of 1.06–1.21. A confidence interval describes the uncertainty around the estimate. Here, the range corresponds to roughly a 6%–21% walking advantage versus placebo. It does not describe every person's response.
An additional analysis expressed the difference in metres: an estimated median advantage of 26.4 metres, with a range of 11.8–40.9 metres. That was an exploratory result, meaning an additional analysis rather than the main test. Walking uphill on a treadmill also cannot translate neatly into a promised distance around the neighbourhood.
What else improved?
The three planned supporting measures also favoured semaglutide in the Lancet report:
- Maximum walking distance five weeks after treatment ended: the treatment ratio was 1.08, with a 95% confidence interval of 1.00–1.16.
- Pain-free walking distance at week 52: the distance before pain began had a treatment ratio of 1.11, with a range of 1.03–1.20.
- PAD-related quality of life: on VascuQoL-6, a six-question score running from 6 to 24, median improvement was 2 points versus 1. Higher scores mean better reported health.
The estimated between-group difference in the quality-of-life score was 1.00 point, with a range of 0.48–1.52. These supporting measures make the walking result more useful: participants also reported changes in symptoms and daily life.
Five weeks of follow-up does not establish that improvements last indefinitely after treatment stops.
Side effects in STRIDE
About half the semaglutide group reported an adverse event—an unwanted medical problem during treatment. Serious events, such as problems requiring hospital care, occurred in about one in five people in either group.
The paper's safety table counts people during treatment, using 396 semaglutide participants and 395 placebo participants. One person assigned placebo never received it.
| Safety finding from the paper | Semaglutide | Placebo |
|---|---|---|
| Any adverse event | 210 (53%) | 182 (46%) |
| Event leading to permanent treatment discontinuation | 28 (7%) | 17 (4%) |
| Any serious adverse event | 74 (19%) | 78 (20%) |
| Serious event leading to permanent treatment discontinuation | 11 (3%) | 13 (3%) |
Reporting an event does not establish that the medicine caused it. Investigators judged serious events possibly or probably treatment-related in five semaglutide participants and six placebo participants. There were no treatment-related deaths.
What critics and later analyses added
A 2025 European Heart Journal commentary highlighted wide differences in individual responses. It also noted missing information about supervised exercise during the study. The group result cannot predict how much farther one person will walk.
A later Diabetes Care analysis in 2025 found no clear difference in walking effects across diabetes duration, obesity status, starting blood-sugar control, or diabetes medication use. This was post hoc, meaning an analysis performed after the main trial. Smaller groups could miss real differences, so the finding supports further study rather than proving identical responses.
As of October 1, 2026, the day this article was written, further STRIDE work had reached ESC Congress on August 31, 2026. The presentation examined walking, symptoms and additional treatment according to background medicines and LDL cholesterol, a blood fat linked to artery disease. It revisited STRIDE; it was not a separate trial in people without diabetes.
What the result means for a prescription
The current U.S. Ozempic prescribing information carries “Revised: 5/2026.” It lists diabetes, cardiovascular-risk and kidney-risk uses, without a separate indication for improving PAD walking distance. An indication is a use written into the label. A positive trial and a new label indication are separate developments.
STRIDE also does not establish long-term protection against amputation. Its walking question differs from the heart-event question in SUSTAIN-6. The semaglutide and heart health guide covers that broader evidence.
Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. STRIDE tested the manufacturer's semaglutide, so its results cannot simply be transferred to a compounded preparation. A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor.
Tirzepatide is another medicine discussed in metabolic care, but STRIDE did not test it or compare it with semaglutide. The tirzepatide product page describes that separate option; these walking numbers belong to semaglutide.
The useful question at a visit
The starting question is whether a person's diagnosis matches the trial population. Diabetes, the reason walking hurts, recent vascular procedures, other medicines and side-effect history all shape that conversation. The semaglutide product page connects the compound to its own visit.
STRIDE tested an addition to usual care. It does not establish that semaglutide replaces prescribed exercise or existing vascular treatment. Novo Nordisk funded the trial and worked with academic investigators on its design and analysis.
At Promise, a licensed provider reviews every request, and not everyone qualifies.
